Citadel Advisors’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.36M | Buy |
200,612
+145,511
| +264% | +$3.97M | ﹤0.01% | 3953 |
|
|
2025
Q4 | $1.5M | Sell |
55,101
-264,231
| -83% | -$6.96M | ﹤0.01% | 6517 |
|
|
2025
Q3 | $8.26M | Sell |
319,332
-59,406
| -16% | -$1.38M | ﹤0.01% | 3551 |
|
|
2025
Q2 | $7.71M | Sell |
378,738
-224,663
| -37% | -$4.37M | ﹤0.01% | 3411 |
|
|
2025
Q1 | $11M | Sell |
603,401
-104,685
| -15% | -$2.34M | ﹤0.01% | 2730 |
|
|
2024
Q4 | $17.9M | Sell |
708,086
-139,195
| -16% | -$3.78M | ﹤0.01% | 2287 |
|
|
2024
Q3 | $28.8M | Buy |
847,281
+526,069
| +164% | +$20M | 0.01% | 1711 |
|
|
2024
Q2 | $11.9M | Buy |
321,212
+235,766
| +276% | +$8.9M | ﹤0.01% | 2559 |
|
|
2024
Q1 | $3.59M | Sell |
85,446
-40,882
| -32% | -$1.68M | ﹤0.01% | 4501 |
|
|
2023
Q4 | $5.01M | Buy |
126,328
+120,403
| +2,032% | +$3.54M | ﹤0.01% | 3786 |
|
|
2023
Q3 | $163K | Sell |
5,925
-84,825
| -93% | -$2.66M | ﹤0.01% | 10225 |
|
|
2023
Q2 | $3.08M | Sell |
90,750
-1,244,796
| -93% | -$42M | ﹤0.01% | 4419 |
|
|
2023
Q1 | $48.1M | Buy |
1,335,546
+575,292
| +76% | +$24.8M | 0.01% | 1105 |
|
|
2022
Q4 | $33.9M | Sell |
760,254
-740,840
| -49% | -$26.4M | 0.01% | 1441 |
|
|
2022
Q3 | $42.2M | Buy |
1,501,094
+457,067
| +44% | +$14M | 0.01% | 1203 |
|
|
2022
Q2 | $28.1M | Sell |
1,044,027
-91,086
| -8% | -$2.65M | 0.01% | 1515 |
|
|
2022
Q1 | $38.7M | Buy |
1,135,113
+65,757
| +6% | +$2.1M | 0.01% | 1319 |
|
|
2021
Q4 | $41.3M | Buy |
1,069,356
+286,295
| +37% | +$12.5M | 0.01% | 1318 |
|
|
2021
Q3 | $42.3M | Buy |
783,061
+411,890
| +111% | +$19.3M | 0.01% | 1266 |
|
|
2021
Q2 | $12.4M | Sell |
371,171
-604,845
| -62% | -$16.6M | ﹤0.01% | 2751 |
|
|
2021
Q1 | $20.1M | Sell |
976,016
-420,500
| -30% | -$9.66M | ﹤0.01% | 1958 |
|
|
2020
Q4 | $24.5M | Buy |
1,396,516
+1,371,367
| +5,453% | +$24.7M | 0.01% | 1601 |
|
|
2020
Q3 | $373K | Sell |
25,149
-34,359
| -58% | -$402K | ﹤0.01% | 7772 |
|
|
2020
Q2 | $774K | Buy |
59,508
+34,997
| +143% | +$155K | ﹤0.01% | 6298 |
|
|
2020
Q1 | $41K | Buy |
24,511
+8,772
| +56% | +$19.8K | ﹤0.01% | 9109 |
|
|
2019
Q4 | $35K | Buy |
+15,739
| New | +$36.5K | ﹤0.01% | 8834 |
|
|
2019
Q1 | – | Sell |
-3,105
| Closed | -$16.3K | – | 9310 |
|
|
2018
Q4 | $9K | Sell |
3,105
-5,530
| -64% | -$27.2K | ﹤0.01% | 8936 |
|
|
2018
Q3 | $59K | Sell |
8,635
-12,307
| -59% | -$86.2K | ﹤0.01% | 8769 |
|
|
2018
Q2 | $159K | Sell |
20,942
-60,050
| -74% | -$803K | ﹤0.01% | 8034 |
|
|
2018
Q1 | $2.83M | Buy |
80,992
+31,690
| +64% | +$1.23M | ﹤0.01% | 3213 |
|
|
2017
Q4 | $2.1M | Sell |
49,302
-60,659
| -55% | -$2.6M | ﹤0.01% | 3569 |
|
|
2017
Q3 | $4.72M | Buy |
109,961
+47,751
| +77% | +$1.79M | ﹤0.01% | 2356 |
|
|
2017
Q2 | $2.3M | Buy |
62,210
+54,506
| +708% | +$2.41M | ﹤0.01% | 2987 |
|
|
2017
Q1 | $417K | Buy |
7,704
+3,699
| +92% | +$193K | ﹤0.01% | 5326 |
|
|
2016
Q4 | $213K | Sell |
4,005
-51,882
| -93% | -$2.95M | ﹤0.01% | 6219 |
|
|
2016
Q3 | $3.39M | Buy |
55,887
+46,172
| +475% | +$2.88M | ﹤0.01% | 2375 |
|
|
2016
Q2 | $640K | Buy |
9,715
+1,966
| +25% | +$125K | ﹤0.01% | 4155 |
|
|
2016
Q1 | $439K | Buy |
7,749
+641
| +9% | +$72.1K | ﹤0.01% | 4589 |
|
|
2015
Q4 | $1.67M | Buy |
7,108
+1,490
| +27% | +$325K | ﹤0.01% | 2946 |
|
|
2015
Q3 | $889K | Sell |
5,618
-45,642
| -89% | -$12.9M | ﹤0.01% | 3973 |
|
|
2015
Q2 | $19.4M | Buy |
51,260
+28,746
| +128% | +$11.4M | 0.02% | 1025 |
|
|
2015
Q1 | $9.41M | Buy |
22,514
+12,597
| +127% | +$4.51M | 0.01% | 1510 |
|
|
2014
Q4 | $2.71M | Sell |
9,917
-992
| -9% | -$247K | ﹤0.01% | 2582 |
|
|
2014
Q3 | $2.12M | Buy |
10,909
+5,525
| +103% | +$1.2M | ﹤0.01% | 2794 |
|
|
2014
Q2 | $1.32M | Buy |
5,384
+212
| +4% | +$47.9K | ﹤0.01% | 3158 |
|
|
2014
Q1 | $1.37M | Sell |
5,172
-2,246
| -30% | -$860K | ﹤0.01% | 3031 |
|
|
2013
Q4 | $2.69M | Sell |
7,418
-15,663
| -68% | -$6.03M | ﹤0.01% | 2235 |
|
|
2013
Q3 | $12.3M | Buy |
23,081
+17,648
| +325% | +$6.05M | 0.02% | 986 |
|
|
2013
Q2 | $1.27M | Buy |
+5,433
| New | +$1.07M | ﹤0.01% | 2940 |
|
Other funds holding CLDX
KCM
VCM
CC
EP
Citadel Advisors's CLDX Position: Q1 2026 in Review
Citadel Advisors increased its Celldex Therapeutics (CLDX) stake by 264% in Q1 2026, buying an estimated $3.97M and bringing the position to 200,612 shares worth $6.36M. The position accounts for ﹤0.01% of the portfolio, ranked #3953.
Citadel Advisors first reported a position in CLDX in Q2 2013 and has held it in 49 quarters since. The position peaked at $48.1M in Q1 2023. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.
- Citadel Advisors held 200,612 shares of Celldex Therapeutics worth $6.36M as of Q1 2026.
- Citadel Advisors bought 145,511 Celldex Therapeutics shares in Q1 2026, an estimated $3.97M.
- Celldex Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3953 holding.
- Citadel Advisors first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 49 quarters since.
- Citadel Advisors's Celldex Therapeutics position peaked at $48.1M in Q1 2023.
- 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.